Gusman, Sluicebox, louieblouie etc I believe the purpose of NICE is similar to the CADTH organization in Canada - to decide on reimbursement for the government plans. CADTH claims to be an independent third party giving the government an objective review of the data and costs. The reality is they are there to provide the government with leverage in price negotiations. The CADTH review in Canada concluded that V’s price had to be reduced by 48% (IIRC) to be cost effective. Their report was similarly slanted against V. Normally drug approval takes 18-24 months. We are 2 weeks away from being 2 years since V’s launch and it’s been 25 months since V’s approval. The cost implications to the drug budgets are substantial and the government will use any means available to delay reimbursement and pressure the manufacturer to reduce costs. The results of this meeting are not surprising and they will not refuse to cover a drug already listed in the Standards of Care and treatment guidelines.
Sounds like you watched a Zoom meeting between AMRN sales reps (and not high level ones from the sounds of it) and a committee responsible for negotiating V prices in the UK - just from reading your notes it looks like it was a total clusterfuck - NOTHING has changed as to how AMRN operates - why the hell was STRENGTH even a topic of conversation? And V doesn't cause fish burps - EPA+DHA does. AMRN reps sound like they knew nothing about the drug they were trying to promote.
Also, you wrote "UK Nice meeting - update sent to KM 13-01-22" - but your post is on 2/4/22 - any reason for the delay in writing KM and posting your comments here?
News 
Market Data 
Discover 
AI
